AEON
HEALTHCAREAEON Biopharma, Inc.
AI Insight
What's Moving AEON Today?
No stock-specific AI insight has been generated for AEON yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.51$1.45
$0.69
Fundamentals
Market Cap$17M
P/E Ratio—
EPS$-6.52
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume24K
Avg Volume (10D)—
Shares Outstanding26.3M
AEON News
23 articles- AEON Biopharma (AEON) director awarded 222,684 RSUs in equity grantStock Titan·Jun 23, 2026
- Director at AEON Biopharma (AEON) granted 222,684 RSUsStock Titan·Jun 23, 2026
- [Form 4] AEON Biopharma, Inc. Insider Trading ActivityStock Titan·Jun 23, 2026
- AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyYahoo Finance·Jun 4, 2026
- Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsightYahoo Finance·Jun 2, 2026
- Why You Might Be Interested In Aeon Co. (M) Bhd. (KLSE:AEON) For Its Upcoming DividendYahoo Finance·May 25, 2026
- AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 14, 2026
- AEON Biopharma Sets Annual Shareholder MeetingYahoo Finance·Apr 24, 2026
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711GlobeNewswire Inc.·Apr 3, 2026
- AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing StandardsYahoo Finance·Apr 3, 2026
- AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar ProgramYahoo Finance·Mar 30, 2026
- Aeon Biopharma announces FDA feedback after Type 2a meetingYahoo Finance·Mar 26, 2026
- AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar ProgramYahoo Finance·Mar 25, 2026
- AEON Biopharma Appoints John Bencich as Chief Financial OfficerYahoo Finance·Mar 9, 2026
- AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual MeetingYahoo Finance·Mar 5, 2026
- AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November TransactionsYahoo Finance·Jan 21, 2026
- An Intrinsic Calculation For Aeon Co. (M) Bhd. (KLSE:AEON) Suggests It's 42% UndervaluedYahoo Finance·Jan 14, 2026
- AEON Biopharma Announces Execution of Exchange Agreement with DaewoongYahoo Finance·Dec 15, 2025
- Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last yearYahoo Finance·Dec 15, 2025
- AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting SchedulingYahoo Finance·Nov 20, 2025
- AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued GrowthYahoo Finance·Nov 14, 2025
- AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis DataYahoo Finance·Nov 13, 2025
- The Returns At Aeon (M) Bhd (KLSE:AEON) Aren't GrowingYahoo Finance·Oct 22, 2025
All 23 articles loaded
Price Data
Open$0.67
Previous Close$0.69
Day High$0.70
Day Low$0.63
52 Week High$1.45
52 Week Low$0.51
52-Week Range
$0.51$1.45
$0.69
Fundamentals
Market Cap$17M
P/E Ratio—
EPS$-6.52
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume24K
Avg Volume (10D)—
Shares Outstanding26.3M
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. The company is headquartered in Newport Beach, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—